Drug
Sok583a1
Sok583a1: highest development phase Phase 3, developed by Sandoz. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| SOK583A1 NCT05282004 | Phase 3 | Neovascular Age-related Macular Degeneration (nAMD) |
| SOK583A1 (40 mg/mL) NCT04864834 | Phase 3 | Neovascular Age-related Macular Degeneration |
| SOK583A1 (40 mg/mL) NCT05161806 | Phase 3 | Neovascular Age-related Macular Degeneration (nAMD) |
Latest
No recent events.
Follow Sok583a1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.